Glitazones have beneficial antihypertensive effects independent of their insulin-sensitizing action. We have studied the effects of pioglitazone and rosiglitazone on the endothelial ability to counteract vascular smooth muscle contractility in genetic hypertension. To achieve this, we measured isometric responses of aortic segments obtained from spontaneously hypertensive rats. The effects of glitazones on endothelial function were studied by assessing the endothelial modulation of phenylephrine-induced isometric contractions (10(-9)-10(-5) M) in the presence or absence of pioglitazone or rosiglitazone (10(-5) M), added directly to an organ bath or orally administered to the rats (pioglitazone, 10 mg/kg). The role of both NO and prostanoids was analyzed by performing experiments in the presence of N(G)-nitro-L-arginine methyl ester (L-NAME) and/or indomethacin (both 10(-5) M) in the organ bath. Concentration-dependent contractions to L-NAME (10(-6)-3 x 10(-4) M) in the presence or absence of glitazones were carried out as an estimation of basal NO release. Pioglitazone, but not rosiglitazone, increased contractile responses to phenylephrine in intact vessels. The contractile responses to phenylephrine obtained in the presence of glitazones were markedly diminished by indomethacin, but enhanced by L-NAME. Analogous results were obtained in aortas from pioglitazone-chronically treated animals. L-NAME concentration-dependent contractions were enhanced by both glitazones. Both glitazones lowered the sensitivity to acetylcholine (10(-9)-10(-5) M). In conclusion, pioglitazone and rosiglitazone alter vascular function differentially and through endothelium-dependent mechanisms. These drugs act over the same pathways on the endothelium where they have a dual action, increasing both production of vasoconstrictor prostanoids and NO. The balance between both vasoactive substances determines the vascular response to glitazones.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2007.08.002DOI Listing

Publication Analysis

Top Keywords

pioglitazone rosiglitazone
20
effects pioglitazone
8
vascular function
8
genetic hypertension
8
presence absence
8
organ bath
8
concentration-dependent contractions
8
contractile responses
8
responses phenylephrine
8
glitazones
7

Similar Publications

Introduction: Masking is a reporting bias where drug safety signals are muffled by elevated reporting of other medications in spontaneous reporting databases. While the impact of masking is often limited, its effect when using restricted designs, such as active comparators, can be consequential.

Methods: We used data from the US Food and Drugs Administration Adverse Event Reporting System (1999Q3-2013Q3) to study masking in a real-world example.

View Article and Find Full Text PDF
Article Synopsis
  • Thiazolidinediones (TZDs), like pioglitazone and rosiglitazone, are effective for treating type II diabetes but raise concerns about their role in heart failure risk, creating safety uncertainties that limit their use.
  • This study employed a multi-omics approach to explore the mechanisms behind TZD-induced heart toxicity, revealing significant alterations in biochemical pathways related to energy metabolism and a shift towards anaerobic glycolysis in heart cells.
  • Findings highlighted disruptions in the glutathione system and identified specific amino acid signatures linked to heart failure, suggesting these could be useful for early detection of TZD-related cardiotoxicity and potential therapeutic targets in the future.
View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma multiforme is a highly aggressive brain tumor, and research has found that the transcription factor RFX1 can inhibit the growth and spread of these tumor cells.
  • The study identified existing medications that could boost RFX1 levels in glioblastoma cells, using bioinformatics and laboratory testing, confirming that drugs like pioglitazone and rosiglitazone effectively promote RFX1.
  • These hypoglycemic medications were shown to decrease cancer cell proliferation and invasion, primarily by reducing metalloproteinase 2 (MMP2) activity, making RFX1 a potential therapeutic target for glioblastoma treatment.
View Article and Find Full Text PDF

Thiazolidinedione derivatives have shown significant potential as targeted cancer therapies by leveraging their various mechanisms of action. These include suppressing cell proliferation, triggering apoptosis, and influencing signaling pathways associated with tumor development. Their multifaceted effects make them promising candidates for advancing cancer treatment strategies.

View Article and Find Full Text PDF

Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?

Naunyn Schmiedebergs Arch Pharmacol

November 2024

Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra, 400019, India.

Polycystic ovarian syndrome (PCOS) is one of the chief causes of infertility in women of reproductive age. Several drugs belonging to the oral contraceptive class have been approved for the treatment of PCOS. Nonetheless, the capability to target only a few symptoms of PCOS and fatal side effects are key hurdles to their use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!